title: Post-chemoradiation anastomotic recurrence in locally advanced rectal cancer: no increased risk associated with distal margin.
abstract: OBJECTIVE
  Anastomotic recurrence after radical sphincter-preserving surgery preceded by neoadjuvant therapy in locally advanced rectal cancer is an uncommon event that merits further assessment. The aim of this study is to analyze the effect of preoperative chemoradiation on the risk of anastomotic recurrence. Based on the initial extension of the tumor, we analyzed whether the distal surgical section was calculated through the virtual initial extension of the rectal tumor.
  
  
  METHODS
  Eligible patients with locally advanced rectal cancer were offered preoperative chemoradiation, sphincter sparing surgery and intraoperative radiation therapy boost.
  
  
  RESULTS
  180 patients were treated with anterior resection (40 %), low anterior resection (45.6 %) and ultra-low anterior resection (14.4 %). With a median follow-up of 41.1 months (0.36-143 months), anastomotic recurrence was diagnosed in 9 patients (5 %). There was no statistical correlation with downstaging (T or N), downsizing effects, or with distance from the lower limit of the residual lesion to the distal margin. Virtual intratumoral surgical section was speculated in 44 patients (3 developed anastomotic recurrence; 6.8 vs 4.8 %, p = 0.482).
  
  
  CONCLUSIONS
  Anastomotic recurrence in patients with rectal cancer treated with neoadjuvant chemoradiation is an infrequent event. Virtual intratumoral surgical sections followed by anastomosis do not contribute to an excessive risk of recurrence. Our findings encourage the development of policies for preservation of the ano-rectal complex in rectal cancer patients.
authors.affiliation: Department of Oncology, Hospital General Universitario Gregorio Marañon, Complutense University, School of Medicine, C/Maiquez 7, 28007, Madrid, Spain.
authors.forename: F A
authors.initials: FA
authors.lastname: Calvo
authors.forename: F
authors.initials: F
authors.lastname: Rivas
authors.forename: C V
authors.initials: CV
authors.lastname: Sole
authors.forename: M
authors.initials: M
authors.lastname: Gómez-Espí
authors.forename: R
authors.initials: R
authors.lastname: Herranz
authors.forename: E
authors.initials: E
authors.lastname: Del Valle
authors.forename: M
authors.initials: M
authors.lastname: Rodríguez
authors.forename: E
authors.initials: E
authors.lastname: Alvarez
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000714:Anastomosis, Surgical / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000209:etiology; D009367:Neoplasm Staging; D059351:Organ Sparing Treatments; D011300:Preoperative Care; D011379:Prognosis; D012004:Rectal Neoplasms / Q000473:pathology / Q000628:therapy*; D012307:Risk Factors